Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease
Conditions
Interventions
lovo-cel
Locations
11
United States
Birmingham, Alabama, United States
Oakland, California, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Bethesda, Maryland, United States
Hackensack, New Jersey, United States
Start Date
February 2, 2015
Primary Completion Date
July 31, 2023
Completion Date
January 30, 2024
Last Updated
March 14, 2025
NCT06820515
NCT07392216
NCT05359991
NCT05170412
NCT06526117
NCT06665997
Lead Sponsor
Genetix Biotherapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions